Results 71 to 80 of about 6,421 (186)

IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19 [PDF]

The coronavirus disease 2019 (COVID-19) pandemic, instigated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has profoundly impacted healthcare infrastructures around the globe.
Admani B., Alhasan K. A., Allen U., Amer Y. S., Ashoor I. F., Bagga A., Bhimma R., Bonilla-Felix M., Boyer O., Bresolin N. L., Coccia P., Dharnidharka V., Duzova A., Esezobor C., Exantus J., Filler G., Haffner D., Hari P., Khan S. A., Koch V., Koh J., Ma A., Mantan M., Marlais M., McCulloch M., Montini G., Morello W., Prestidge C., Raina R., Restrepo J. M., Rodriguez L. I., Safouh H., Sethi S. K., Smith J. M., Temsah M. -H., Trnka P., Vasudevan A., Zhong X.   +37 more
core   +1 more source

An Intersectional Analysis of Social Deprivation and Patient Characteristics on Nirmatrelvir-Ritonavir for Treatment of COVID-19 in U.S. Primary Care Practices, 2021 to 2023

Journal of Primary Care & Community Health
Objective: Calculate rates of nirmatrelvir-ritonavir prescription and assess area-level social deprivation as an effect modifier of patient characteristics on nirmatrelvir-ritonavir for the treatment of COVID-19.
Esther E. Velásquez, Neil S. Kamdar, Nathaniel Hendrix, Xiaoyu Wang, Robert L. Phillips, David H. Rehkopf   +5 more
doaj   +1 more source

Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy [PDF]

Introduction: Scarce real-life data exists for COVID-19 management in hematologic disease (HD) patients in the Omicron era. Purpose: To assess the current clinical management and outcome of SARS-CoV-2 infection diagnosed, identify the risk factors for ...
Aiello, Tommaso Francesco, Arellano, E., Aroca, C., Arroyo, I., Avendaño-Pita, A., Campos, D., Cedillo, Á., Chorao, P., Cuesta-Casas, M., Garcia Cadenas, Irene, Garcia-Gutierrez, V., González-Santillana, C., Guerreiro, M., Gómez, M.A., Heras, I., Hernández-Rivas, J.Á., Labrador, J., Lopez-Jimenez, J., López-Corral, L., Martino Bofarull, Rodrigo, Mico-Cerdá, M., Morell, J., Olave, M.T., Piñana, J.L., Rodriguez-Galvez, P., Roldán-Pérez, A., Solano, C., Soler-Espejo, E., Universitat Autònoma de Barcelona, Vazquez, L., Vidal, C.G.   +30 more
core   +1 more source

Patterns of use of oral antivirals for COVID-19 in people 70 years and over in Victoria, Australia: a linked data study

BMC Infectious Diseases
Background Two oral antivirals for treatment of COVID-19 are available in Australia, nirmatrelvir-ritonavir, which is recommended, and molnupiravir, which is approved for use when nirmatrelvir-ritonavir is contraindicated.
Laura J. Edwards, Anish Scaria, Allen C. Cheng, Janaki Amin, Elizabeth J. Robinson, Caroline Sumpton, Bette Liu   +6 more
doaj   +1 more source

Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis

Tungs’ Medical Journal
Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly reduced the risk of coronavirus disease 2019 (COVID-19)-related ...
Chienhsiu Huang, Sufang Kuo, Lichen Lin
doaj   +1 more source

ORCHESTRA Delphi consensus: clinical management of SARS-CoV-2 infection in people with HIV [PDF]

Objectives: The interaction between HIV and COVID-19 resulted in a syndemic that showed an excess burden of disease for people with HIV (PWH). Four years of the COVID-19 pandemic have raised many unsolved questions about the optimal care of COVID-19 in ...
Alemán-Rodríguez, Aurora, Amicucci, Armando, Antinori, Andrea, Augello, Matteo, Azzini, Anna Maria, Bai, Francesca, Baño, Jesús Rodríguez, Barrera-Pulido, Lydia, Berenguer, Juan, Bhagani, Sanjay, Bonnet, Fabrice, Bonora, Stefano, Burns, Fiona, Caponcello, Maria Giulia, Cataudella, Salvatore, Cingolani, Antonella, Conti, Michela, Costantini, Andrea, Cozzi-Lepri, Alessandro, Cubero-Aranda, Lola, De la Serna, Almudena, De Nardo, Pasquale, de Vedia, Lautaro, De Vito, Andrea, Dellacasa, Chiara, Di Biagio, Antonio, Elvire Roukens, Anna Helena, Esvan, Rozenn, Fasani, Giada, Fornaro, Giacomo, Fusco, Francesco Maria, Gatti, Milo, Gentilotti, Elisa, Giacomelli, Andrea, Giannella, Maddalena, Hara, Gabriel Levy, Hara, Gabriel Levy, Hentzien, Maxime, Hidalgo-Cespedes, Ana Belén, Hojman, Martin, Hrom-Hrom, Ioana, Lambertenghi, Lorenza, Lapadula, Giuseppe, Lichtner, Miriam, Lo Caputo, Sergio, Maccarrone, Gaia, Marchetti, Giulia, Martinez, Esteban, Marzolla, Domenico, Mazzotta, Valentina, Mirandola, Massimo, Monforte, Antonella d'Arminio, Ole Jensen, Björn-Erik, Olivares-Navarro, Paula, Palacios-Baena, Zaira R., Palomo, Virginia, Paola, Cinque, Parczewski, Miłosz, Pascale, Renato, Pellicanò, Giovanni, Perno, Carlo Federico, Pezzani, Maria Diletta, Piconi, Stefania, Pipitò, Luca, Puoti, Massimo, Quiros-Roldan, Eugenia, Rinaldi, Matteo, Rockstroh, Juergen, Rossi, Elisa, Rusconi, Stefano, Sanchez-Gárcia, María Isabel, Sarmati, Loredana, Savinelli, Stefano, Savoldi, Alessia, Sönnerborg, Anders, Sued, Omar, Tacconelli, Evelina, Tavelli, Alessandro, Tazza, Beatrice, Toschi, Alice, Van Der Valk, Marc, Vergori, Alessandra   +81 more
core   +1 more source

Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia

BMC Infectious Diseases
Background The effect of nirmatrelvir/ritonavir on preventing post-COVID condition (PCC) in the BA4, BA5, and XBB Omicron predominant periods is not well understood.
Ee Vien Low, Mohan Dass Pathmanathan, Yi Yang Ten, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Mastura Ismail, Azah Abdul Samad, Kalaiarasu M. Peariasamy   +10 more
doaj   +1 more source

Incidence of COVID-19 Symptom Rebound After Treatment with Remdesivir

Infectious Disease Reports
Background/Objectives: Recent in vitro data suggest that remdesivir might be less likely than nirmatrelvir–ritonavir to be associated with COVID-19 rebound. We compared the incidence of symptom rebound in our remdesivir-treated cohort with rates reported
Kalpana Gupta, William J. O’Brien, Judith Strymish, Anna Chen, Katherine Linsenmeyer, Rebecca Madjarov, Michael E. Charness   +6 more
doaj   +1 more source

Successful use of nirmatrelvir/ritonavir in immunocompromised patients with persistent and/or relapsing COVID-19 [PDF]

, 2023
Bartoloni, Alessandro, Basile, Gregorio, Campolmi, Irene, Ciurleo, Greta, Coppi, Marco, di Dio, Marta, Graziani, Lucia, Malentacchi, Francesca, Manciulli, Tommaso, Mattei, Marta, Morettini, Alessandro, Parronchi, Paola, Rossolini, Gian Maria, Spinicci, Michele, Tomassetti, Sara   +14 more
core   +1 more source

Nirmatrelvir-ritonavir for COVID-19 [PDF]

Canadian Medical Association Journal, 2022
McDonald, Emily G, Lee, Todd C
openaire   +2 more sources